TCR2 Therapeutics Inc. buy quelbe60
Start price
16.10.22
/
50%
€1.68
Target price
16.10.23
-
Performance (%)
-6.83%
End price
30.10.22
€1.56
Summary
This prediction ended on 30.10.22 with a price of €1.56. With a performance of -6.83%, the BUY prediction by quelbe60 finished with a loss. quelbe60 has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| TCR2 Therapeutics Inc. | - | - | - | - |
| iShares Core DAX® | 1,01 % | 2,70 % | 4,36 % | 51,69 % |
| iShares Nasdaq 100 | -6,47 % | -8,77 % | 18,00 % | 67,99 % |
| iShares Nikkei 225® | -6,52 % | -12,58 % | 40,91 % | 57,11 % |
| iShares S&P 500 | -2,72 % | -1,75 % | 16,97 % | 58,87 % |
According to quelbe60 what are the pros and cons of TCR2 Therapeutics Inc. for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Cons
Comments by quelbe60 for this prediction
In the thread Tcr2 Therapeutics Inc. diskutieren
Buy TCR2 Therapeutics Inc.